The global dengue fever treatment market is on the verge of significant expansion, with projections indicating a leap from USD 877.82 million in 2023 to a staggering USD 5435.25 million by 2033. This impressive growth, driven by a compound annual growth rate (CAGR) of 20%, highlights the escalating prevalence of dengue fever and the urgent need for innovative and effective treatment solutions.
Dengue fever, a mosquito-borne viral infection, is characterized by severe flu-like symptoms and has emerged as one of the most widespread mosquito-borne diseases globally. Annually, over 400 million individuals are infected, presenting a substantial public health challenge. Traditionally most prevalent in tropical and subtropical regions, dengue fever cases are now increasingly reported in temperate areas, influenced by factors such as climate change and increased global travel.
Secure Your Sample Report and Stay Ahead in the Dynamic Dengue Fever Treatment Market
Currently, there is no specific antiviral treatment available for dengue fever. The standard approach to managing the disease is primarily supportive, including rest, hydration, and medications to alleviate fever and pain. In more severe cases, patients may require hospitalization for intravenous fluids and blood transfusions to manage complications.
The forecasted growth in the dengue fever treatment market underscores the urgent need for advancements in supportive care and potential development of targeted therapies. As the global incidence of dengue fever continues to rise, driven by environmental changes and increased mobility, the healthcare industry is called to action to address this escalating concern.
The Market Growth is being driven by a Number of Factors, Including:
- Increasing incidence of dengue fever
- Rising awareness of dengue fever and its treatment options
- Growing government and private investments in dengue fever research and development
- Development of new and more effective dengue fever treatments
Key Takeaways from the Dengue Fever Treatment Market Report:
- The global dengue fever treatment market is expected to grow at a CAGR of 20% from 2023 to 2033.
- The market growth is being driven by a number of factors, including increasing incidence of dengue fever, rising awareness of dengue fever and its treatment options, growing government and private investments in dengue fever research and development, and development of new and more effective dengue fever treatments.
- The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to account for the largest share of the market during the forecast period.
- The hospital pharmacies segment is expected to account for the largest share of the market during the forecast period.
- The hospitals segment is expected to account for the largest share of the market during the forecast period.
Emerging trends in the dengue fever treatment market:
- There is a growing interest in the development of new antiviral drugs for the treatment of dengue fever. A number of pharmaceutical companies are currently developing antiviral drugs that target different stages of the dengue virus life cycle.
- There is also a growing interest in the development of vaccines for the prevention of dengue fever. A number of pharmaceutical companies are currently developing vaccines that target all four serotypes of the dengue virus.
- The use of artificial intelligence (AI) and machine learning (ML) is becoming increasingly common in the dengue fever treatment market. AI and ML are being used to develop new diagnostic tools, predict disease outbreaks, and personalize treatment plans.
The dengue fever treatment market is expected to witness significant growth in the coming years. The increasing incidence of dengue fever and the growing awareness of its treatment options are driving the market growth. The development of new and more effective dengue fever treatments is also expected to contribute to the market growth.
Elevate Your Strategy with Full Report Access – Get It Now
Market Competition:
Key players in the Dengue Fever Treatment Market are Mylan N.V, Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi, and Takeda Pharmaceutical Company Limited among other global players.
- In March 2021, Takeda Pharmaceutical Company Limited announced the approval of its TAK-003 dengue vaccine candidate by the European Medicines Agency (EMA), currently under investigation for preventing any outbreaks in individuals aged 4 to 60. The company also intends to apply for regulatory approvals in Argentina, Brazil, Columbia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand through 2021.
- In December 2021, Kao Corporation announced the launch of a campaign to reduce the spread of dengue fever. Kao used its original technology to develop similar products as part of the initiative. Kao distributed 80,000 units of the product in partnership with the Thai Ministry of Public Health and donated 6.5 Million Thai baht to the Ministry in total, which includes the items. In addition, the initiative enhanced the demonstration and research efforts as well as raised overall awareness of Dengue disease.
Key Segments Profiled in the Dengue Fever Treatment Industry Survey:
Type:
- Drug
- Vaccines
Route of Administration:
- Oral
- Parenteral
End-User:
- Hospital
- Homecare
- Specialty Clinics
- Others
Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
